Group One Trading’s MoonLake Immunotherapeutics MLTX Stock Holding History

Group One Trading’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$402K	Sell	21,563 -8,913	-29%	-$148K	﹤0.01%	3544
2025 Q4	$402K	Buy	30,476 +15,007	+97%	+$177K	﹤0.01%	3736
2025 Q3	$111K	Buy	+15,469	New	+$806K	﹤0.01%	5242
2024 Q3	–	Sell	-6,832	Closed	-$320K	–	7072
2024 Q2	$300K	Sell	6,832 -6,688	-49%	-$283K	﹤0.01%	3044
2024 Q1	$679K	Buy	+13,520	New	+$733K	﹤0.01%	2449
2023 Q4	–	Sell	-4,234	Closed	-$218K	–	7871
2023 Q3	$241K	Buy	+4,234	New	+$234K	﹤0.01%	3648

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Group One Trading's MLTX Position: Q1 2026 in Review

Group One Trading reduced its MoonLake Immunotherapeutics (MLTX) stake by 29% in Q1 2026, selling an estimated $148K and leaving 21,563 shares worth $402K. The position accounts for ﹤0.01% of the portfolio, ranked #3544.

Group One Trading first reported a position in MLTX in Q3 2023 and has held it in 6 quarters since. The position peaked at $679K in Q1 2024. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

Group One Trading held 21,563 shares of MoonLake Immunotherapeutics worth $402K as of Q1 2026.
Group One Trading sold 8,913 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $148K.
MoonLake Immunotherapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #3544 holding.
Group One Trading first reported a position in MoonLake Immunotherapeutics in Q3 2023 and has held it in 6 quarters since.
Group One Trading's MoonLake Immunotherapeutics position peaked at $679K in Q1 2024.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.